BRAD P GLICK
- Type
- Physician · Allopathic & Osteopathic Physicians / Dermatology
- Where
- MARGATE, FL
- NPI
- 1235134818
- Received
- $2,041,774 in 2,271 records, 2019 to 2025 ($2,041,450 general, $324 research)
- As principal investigator
- $2,020,988 of research payments to others in 714 records
- Source
- CMS Open Payments search ↗
On this site
- FEC donor: GLICK, BRAD P. Fuzzy (same full name with a middle name or initial, one FEC donor in that state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 419 | $405,391 |
| 2024 | General payment | 426 | $380,351 |
| 2023 | General payment | 349 | $367,021 |
| 2022 | General payment | 333 | $321,954 |
| 2021 | General payment | 217 | $197,871 |
| 2020 | General payment | 195 | $155,308 |
| 2020 | Research payment | 1 | $324 |
| 2019 | General payment | 331 | $213,551 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 549 | $1,455,038 |
| Consulting Fee | 130 | $320,499 |
| Travel and Lodging | 259 | $105,138 |
| Honoraria | 25 | $65,425 |
| Food and Beverage | 1,274 | $50,280 |
| Compensation for serving as faculty or as a speaker for a medical education program | 11 | $27,800 |
| Grant | 2 | $13,740 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 2 | $3,000 |
| Education | 17 | $409 |
| Research payment | 1 | $324 |
| Gift | 1 | $116 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-30 | ABBVIE INC. | $4,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-23 | LEO Pharma Inc. | $4,525 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-12-23 | UCB, Inc. | $49 | Travel and Lodging | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-23 | UCB, Inc. | $44 | Travel and Lodging | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-19 | GENZYME CORPORATION | $41 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-17 | Galderma Laboratories, L.P. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-17 | LEO Pharma Inc. | $11 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-12-17 | LEO Pharma Inc. | $3 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-12-16 | Incyte Corporation | $94 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-16 | Incyte Corporation | $21 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-12-13 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-12 | Galderma Laboratories, L.P. | $3,120 | Consulting Fee | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-12 | Amgen Inc. | $2 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-12-10 | Janssen Biotech, Inc. | $25 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-12-09 | LEO Pharma Inc. | $124 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-12-09 | Arcutis Biotherapeutics, Inc. | $121 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-12-09 | LNHC, Inc | $11 | Food and Beverage | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-12-09 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-08 | ABBVIE INC. | $123 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-08 | Galderma Laboratories, L.P. | $10 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-06 | Galderma Laboratories, L.P. | $50 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-06 | Galderma Laboratories, L.P. | $20 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-06 | Galderma Laboratories, L.P. | $8 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-04 | Janssen Biotech, Inc. | $22 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-12-03 | UCB, Inc. | $4,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-12-03 | Arcutis Biotherapeutics, Inc. | $3,375 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-12-03 | Eli Lilly and Company | $3,200 | Consulting Fee | Cash or cash equivalent | EBGLYSS Drug, Immunology | 2025 | |
| 2025-12-03 | Eli Lilly and Company | $2,800 | Consulting Fee | Cash or cash equivalent | EBGLYSS Drug, Immunology | 2025 | |
| 2025-12-03 | Arcutis Biotherapeutics, Inc. | $21 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-12-03 | Botanix SB Inc | $3 | Food and Beverage | In-kind items and services | SOFDRA Drug, DERMATOLOGY | 2025 | |
| 2025-12-02 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-12-01 | Ortho Dermatologics, a division of Bausch Health US, LLC | $4,500 | Consulting Fee | Cash or cash equivalent | SILIQ Drug, Dermatology | 2025 | |
| 2025-12-01 | Ortho Dermatologics, a division of Bausch Health US, LLC | $296 | Travel and Lodging | In-kind items and services | SILIQ Drug, Dermatology | 2025 | |
| 2025-12-01 | SUN PHARMACEUTICAL INDUSTRIES INC. | $21 | Food and Beverage | In-kind items and services | ILUMYA Biological, Dermatology | 2025 | |
| 2025-11-21 | LEO Pharma Inc. | $5,123 | Consulting Fee | Cash or cash equivalent | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-11-21 | LEO Pharma Inc. | $4,073 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-11-21 | LEO Pharma Inc. | $2,263 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-11-21 | LEO Pharma Inc. | $2,263 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-11-19 | Arcutis Biotherapeutics, Inc. | $1,875 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-19 | Regeneron Healthcare Solutions, Inc. | $25 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-11-18 | Incyte Corporation | $547 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-18 | Incyte Corporation | $124 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-17 | Ortho Dermatologics, a division of Bausch Health US, LLC | $36 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-17 | GENZYME CORPORATION | $31 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-14 | Arcutis Biotherapeutics, Inc. | $1,875 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-12 | Arcutis Biotherapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-11 | UCB, Inc. | $2,250 | Consulting Fee | Cash or cash equivalent | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-11 | LEO Pharma Inc. | $23 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-11-11 | Galderma Laboratories, L.P. | $8 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-10 | Galderma Laboratories, L.P. | $13 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-10 | Galderma Laboratories, L.P. | $9 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-07 | ABBVIE INC. | $2,550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-07 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | EBGLYSS Drug, Immunology | 2025 | |
| 2025-11-06 | LNHC, Inc | $2,625 | Honoraria | Cash or cash equivalent | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-11-06 | UCB, Inc. | $139 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-11-06 | Organon Llc | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-05 | Incyte Corporation | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-04 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-04 | Regeneron Healthcare Solutions, Inc. | $3 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-11-03 | Regeneron Healthcare Solutions, Inc. | $28 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-30 | Eli Lilly and Company | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TALTZ Drug, Immunology | 2025 | |
| 2025-10-29 | Incyte Corporation | $124 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-29 | MAYNE PHARMA COMMERCIAL LLC | $5 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-29 | Galderma Laboratories, L.P. | $4 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-29 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-28 | STRATA Skin Sciences, Inc. | $11 | Food and Beverage | In-kind items and services | XTRAC Device, Dermatology | 2025 | |
| 2025-10-27 | GENZYME CORPORATION | $32 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-26 | Amgen Inc. | $126 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-10-25 | LNHC, Inc | $188 | Travel and Lodging | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-10-25 | ABBVIE INC. | $54 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-25 | UCB, Inc. | $45 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-10-24 | SUN PHARMACEUTICAL INDUSTRIES INC. | $88 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-23 | E.R. Squibb & Sons, L.L.C. | $20 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-10-23 | E.R. Squibb & Sons, L.L.C. | $20 | Food and Beverage | Cash or cash equivalent | Sotyktu Drug, Immunology | 2025 | |
| 2025-10-22 | Regeneron Healthcare Solutions, Inc. | $33 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-21 | ABBVIE INC. | $5,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-21 | Regeneron Healthcare Solutions, Inc. | $5,551 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-21 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-21 | Organon Llc | $9 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-21 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-20 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-20 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-18 | GENZYME CORPORATION | $11,284 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-18 | Janssen Biotech, Inc. | $4,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-17 | Regeneron Healthcare Solutions, Inc. | $767 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-17 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-17 | Galderma Laboratories, L.P. | $5 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-16 | Kowa Pharmaceuticals America, Inc. | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-10-16 | Incyte Corporation | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-16 | Janssen Biotech, Inc. | $149 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-10-14 | ABBVIE INC. | $5,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-14 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | EBGLYSS Drug, Immunology | 2025 | |
| 2025-10-13 | Regeneron Healthcare Solutions, Inc. | $24 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-13 | Galderma Laboratories, L.P. | $6 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-13 | Regeneron Healthcare Solutions, Inc. | $1 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-10 | LEO Pharma Inc. | $10 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-10-10 | LEO Pharma Inc. | $9 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-10-09 | Lilly USA, LLC | $2,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | EBGLYSS Drug, Immunology | 2025 | |
| 2025-10-09 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-06 | GENZYME CORPORATION | $29 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-05 | Ortho Dermatologics, a division of Bausch Health US, LLC | $681 | Travel and Lodging | In-kind items and services | SILIQ Drug, Dermatology | 2025 | |
| 2025-10-05 | Ortho Dermatologics, a division of Bausch Health US, LLC | $68 | Food and Beverage | In-kind items and services | SILIQ Drug, Dermatology | 2025 | |
| 2025-10-03 | Galderma Laboratories, L.P. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-03 | Arcutis Biotherapeutics, Inc. | $1,875 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-10-01 | Arcutis Biotherapeutics, Inc. | $1,875 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-10-01 | PFIZER INC. | $728 | Travel and Lodging | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-10-01 | UCB, Inc. | $25 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-30 | PFIZER INC. | $4,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-30 | ABBVIE INC. | $674 | Travel and Lodging | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-09-26 | Lilly USA, LLC | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | EBGLYSS Drug, Immunology | 2025 | |
| 2025-09-25 | Organon Llc | $1,600 | Honoraria | Cash or cash equivalent | VTAMA Drug, Dermatology | 2025 | |
| 2025-09-25 | Organon Llc | $1,600 | Honoraria | Cash or cash equivalent | VTAMA Drug, Dermatology | 2025 | |
| 2025-09-25 | PFIZER INC. | $117 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-24 | Arcutis Biotherapeutics, Inc. | $3,375 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-24 | LEO Pharma Inc. | $84 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-09-24 | GENZYME CORPORATION | $26 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-24 | Organon Llc | $24 | Travel and Lodging | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-09-22 | Amgen Inc. | $3,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-09-22 | Amgen Inc. | $3,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-09-22 | Amgen Inc. | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OTEZLA Drug, Inflammation | 2025 | |
| 2025-09-22 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-22 | LNHC, Inc | $17 | Food and Beverage | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-09-19 | Amgen Inc. | $1,871 | Travel and Lodging | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-09-19 | Amgen Inc. | $8 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-09-19 | Amgen Inc. | $7 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-09-18 | Amgen Inc. | $122 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-09-17 | Incyte Corporation | $53 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-09-17 | Incyte Corporation | $41 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-09-17 | Janssen Biotech, Inc. | $23 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-16 | Amgen Inc. | $386 | Travel and Lodging | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-09-16 | UCB, Inc. | $120 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-09-16 | UCB, Inc. | $105 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-09-16 | Organon Llc | $11 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-15 | GENZYME CORPORATION | $25 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-11 | Organon Llc | $3,200 | Honoraria | Cash or cash equivalent | VTAMA Drug, Dermatology | 2025 | |
| 2025-09-11 | Botanix SB Inc | $18 | Food and Beverage | In-kind items and services | SOFDRA Drug, DERMATOLOGY | 2025 | |
| 2025-09-10 | GENZYME CORPORATION | $22 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-08 | ABBVIE INC. | $4,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-09-06 | Galderma Laboratories, L.P. | $2,340 | Consulting Fee | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-09-04 | Organon Llc | $99 | Food and Beverage | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-09-03 | LNHC, Inc | $225 | Travel and Lodging | Cash or cash equivalent | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-09-03 | LNHC, Inc | $35 | Food and Beverage | Cash or cash equivalent | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-09-03 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-03 | Galderma Laboratories, L.P. | $2 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-29 | Lilly USA, LLC | $2,400 | Consulting Fee | Cash or cash equivalent | TALTZ Drug, Immunology | 2025 | |
| 2025-08-28 | Organon Llc | $3,200 | Honoraria | Cash or cash equivalent | VTAMA Drug, Dermatology | 2025 | |
| 2025-08-27 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-08-27 | Regeneron Healthcare Solutions, Inc. | $16 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-25 | PFIZER INC. | $750 | Consulting Fee | Cash or cash equivalent | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-25 | Arcutis Biotherapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-21 | Organon Llc | $93 | Food and Beverage | In-kind items and services | VTAMA Drug, Dermatology | 2025 | |
| 2025-08-20 | Janssen Biotech, Inc. | $21 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-19 | UCB, Inc. | $9,000 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-19 | UCB, Inc. | $34 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-18 | Amgen Inc. | $29 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-08-15 | Galderma Laboratories, L.P. | $3,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-14 | ABBVIE INC. | $4,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-14 | Arcutis Biotherapeutics, Inc. | $1,500 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | $402 | Travel and Lodging | In-kind items and services | SPEVIGO Drug, IMMUNOLOGY | 2025 | |
| 2025-08-13 | LNHC, Inc | $6,000 | Honoraria | Cash or cash equivalent | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-08-13 | Lilly USA, LLC | $27 | Food and Beverage | In-kind items and services | EBGLYSS Drug, Immunology | 2025 | |
| 2025-08-13 | MAYNE PHARMA COMMERCIAL LLC | $8 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-13 | Arcutis Biotherapeutics, Inc. | $7 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-12 | Ortho Dermatologics, a division of Bausch Health US, LLC | $45 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-12 | Regeneron Healthcare Solutions, Inc. | $19 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-08-11 | Regeneron Healthcare Solutions, Inc. | $27 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-09 | LNHC, Inc | $1,035 | Travel and Lodging | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-08-09 | LNHC, Inc | $207 | Travel and Lodging | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-08-09 | LNHC, Inc | $116 | Gift | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-08-09 | LNHC, Inc | $80 | Food and Beverage | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-08-09 | LNHC, Inc | $71 | Food and Beverage | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-08-09 | LNHC, Inc | $65 | Food and Beverage | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-08-09 | LNHC, Inc | $45 | Food and Beverage | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-08-09 | LNHC, Inc | $36 | Food and Beverage | In-kind items and services | ZELSUVMI Drug, DERMATOLOGY | 2025 | |
| 2025-08-07 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-06 | Galderma Laboratories, L.P. | $697 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-06 | Galderma Laboratories, L.P. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-06 | Galderma Laboratories, L.P. | $125 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-06 | Galderma Laboratories, L.P. | $30 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-06 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-05 | PFIZER INC. | $4,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-05 | PFIZER INC. | $709 | Travel and Lodging | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-05 | Janssen Biotech, Inc. | $25 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-04 | Biofrontera Inc. | $13,561 | Grant | In-kind items and services | RHODOLED XL Device, DERMATOLOGY | 2025 | |
| 2025-08-04 | Biofrontera Inc. | $179 | Grant | In-kind items and services | AMELUZ Drug, DERMATOLOGY | 2025 | |
| 2025-08-04 | Incyte Corporation | $26 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-08-04 | UCB, Inc. | $5 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-08-02 | UCB, Inc. | $30 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-02 | UCB, Inc. | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-02 | UCB, Inc. | $10 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-02 | UCB, Inc. | $9 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-02 | UCB, Inc. | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-01 | UCB, Inc. | $586 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-01 | UCB, Inc. | $257 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-01 | UCB, Inc. | $201 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-01 | UCB, Inc. | $125 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-01 | UCB, Inc. | $65 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-07-30 | PFIZER INC. | $122 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-30 | Regeneron Healthcare Solutions, Inc. | $17 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-07-29 | Galderma Laboratories, L.P. | $170 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 |
The latest 200 records of 2,271.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $3,537 | A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upad | 2025 |
| 2025-12-31 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $1,529 | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult | 2025 |
| 2025-12-24 | Amgen Inc. | Gsi Clinical Research | $7,100 | A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Saf | 2025 |
| 2025-12-24 | Amgen Inc. | Gsi Clinical Research | $3,600 | A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability o | 2025 |
| 2025-12-04 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $1,892 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-12-04 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $3,104 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit | 2025 |
| 2025-12-04 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $21,865 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-12-01 | Incyte Corporation | Gsi Clinical Research | $47 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-12-01 | Incyte Corporation | Gsi Clinical Research | $1 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-12-01 | Incyte Corporation | Gsi Clinical Research | $4 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-11-12 | Incyte Corporation | Gsi Clinical Research | $1,800 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2025 |
| 2025-11-12 | Incyte Corporation | Gsi Clinical Research | $1,500 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2025 |
| 2025-11-05 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $35,066 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-11-04 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $2,002 | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With M | 2025 |
| 2025-11-04 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $2,167 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-11-04 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $7,001 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit | 2025 |
| 2025-10-29 | SANOFI US SERVICES INC. | Gsi Clinical Research | $2,000 | Registry to characterize the patients who receive Dupixent for PN in a real-world setting | 2025 |
| 2025-10-15 | Incyte Corporation | Gsi Clinical Research | $10,000 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-10-15 | Incyte Corporation | Gsi Clinical Research | $1,200 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-10-15 | Incyte Corporation | Gsi Clinical Research | $2,500 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-10-13 | Incyte Corporation | Gsi Clinical Research | $500 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-10-13 | Incyte Corporation | Gsi Clinical Research | $1,800 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-10-13 | Incyte Corporation | Gsi Clinical Research | $1,500 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-10-09 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $34,800 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-09-10 | Incyte Corporation | Gsi Clinical Research | $1,413 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2025 |
| 2025-09-03 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $2,502 | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With M | 2025 |
| 2025-09-03 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $3,004 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit | 2025 |
| 2025-08-06 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $500 | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With M | 2025 |
| 2025-08-05 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $3,000 | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Sc | 2025 |
| 2025-07-09 | Incyte Corporation | Gsi Clinical Research | $1,984 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2025 |
| 2025-07-02 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $1,636 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-07-02 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $500 | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With M | 2025 |
| 2025-07-02 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $3,854 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit | 2025 |
| 2025-07-02 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $1,695 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-07-02 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $2,380 | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Sc | 2025 |
| 2025-06-03 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $2,054 | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With M | 2025 |
| 2025-06-03 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $3,681 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-06-03 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $6,858 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit | 2025 |
| 2025-05-28 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $2,628 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-28 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $2,628 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-21 | Regeneron Pharmaceuticals, Inc. | GSI CLINICAL RESEARCH LLC | $400 | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $1,895 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $1,895 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $2,526 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $1,895 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $250 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $250 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $1,895 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $508 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $454 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $1,895 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $3,388 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-05-07 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $2,054 | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With M | 2025 |
| 2025-05-07 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $4,483 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $1,895 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $2,526 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $1,895 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $254 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $2,526 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $2,526 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $1,895 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $254 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $704 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $250 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-07 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $250 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-05-06 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $5,500 | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Sc | 2025 |
| 2025-05-02 | Incyte Corporation | Gsi Clinical Research | $1,172 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $2,628 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $2,628 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-04-09 | Incyte Corporation | Gsi Clinical Research | $2,205 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2025 |
| 2025-04-03 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $1,338 | A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants Wit | 2025 |
| 2025-04-03 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $2,291 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-04-03 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $2,054 | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With M | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $10 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $16 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $26 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $121 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $95 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $49 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $62 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $135 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $49 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $49 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $68 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $54 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $64 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $14 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $59 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $12 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $49 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-04-02 | Incyte Corporation | Gsi Clinical Research | $49 | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenit | 2025 |
| 2025-03-24 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $2,628 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-03-24 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $4,500 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-03-24 | Janssen Research & Development, LLC | Gsi Clinic Rsrch | $4,500 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | 2025 |
| 2025-03-12 | Incyte Corporation | Gsi Clinical Research | $1,393 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2025 |
| 2025-03-07 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $6,345 | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Gen | 2025 |
| 2025-03-07 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $1,001 | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participa | 2025 |
| 2025-03-07 | ABBVIE INC. | GSI CLINICAL RESEARCH LLC | $6,587 | M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Partic | 2025 |
| 2025-03-03 | Incyte Corporation | Gsi Clinical Research | $24 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2025 |
| 2025-03-03 | Incyte Corporation | Gsi Clinical Research | $0 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Parti | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Margate, FL, county Broward County, FL, state Florida; placed by its city name.
| Measure | Place (city or town) Margate, FL | County Broward County, FL | State Florida |
|---|---|---|---|
| Population B01003 | 59,198 | 1,977,129 | 22,416,077 |
| Population, 2020 census P1 | 58,712 | 1,944,375 | 21,538,187 |
| Median age B01002 | 45.0 | 41.3 | 42.6 |
| Under 18 B01001 | 17.3% | 20.8% | 19.5% |
| 65 and over B01001 | 23.5% | 17.9% | 21.3% |
| Households B11001 | 24,297 | 753,956 | 8,752,810 |
| Foreign born B05002 | 40.6% | 36.9% | 21.9% |
| Median household income B19013 | $62,450 | $77,633 | $74,568 |
| Median family income B19113 | $84,709 | $92,109 | $89,891 |
| Per capita income B19301 | $34,214 | $43,052 | $42,609 |
| Poverty rate B17001 | 12.1% | 12.2% | 12.6% |
| Unemployment rate B23025 | 4.1% | 5.4% | 4.8% |
| Civilian labor force B23025 | 31,671 | 1,068,318 | 11,016,578 |
| Mean commute (minutes) B08013 | 30.7 | 29.1 | 28.0 |
| Bachelor's degree or higher B15003 | 24.7% | 36.7% | 34.1% |
| Housing units B25001 | 26,356 | 866,019 | 10,256,470 |
| Owner-occupied B25003 | 77.2% | 63.6% | 67.6% |
| Renters B25003 | 22.8% | 36.4% | 32.4% |
| Median home value B25077 | $316,200 | $414,600 | $359,000 |
| Median gross rent B25064 | $1,750 | $1,907 | $1,669 |
| White, not Hispanic B03002 | 29.2% | 30.7% | 50.4% |
| Black B03002 | 33.2% | 27.4% | 14.6% |
| Hispanic or Latino B03002 | 26.7% | 32.8% | 27.4% |
| Asian B03002 | 3.2% | 3.6% | 2.9% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 4.4% in Sep 2026 (4.2% a year earlier); per capita personal income $78,345 in 2025, up 38% in five years (+11.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Margate, FL.
Comments